Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 22, 2026
Chubb (CB) Q2 2026 Earnings: Core Operating Income Rises +14.6% as Combined Ratio Improves

Chubb (CB) Q2 2026 Earnings: Core Operating Income Rises +14.6% as Combined Ratio Improves

Key Takeaways

  • Chubb reported Q2 2026 net income of $2.85 billion, or $7.30 per share, down 3.8% year-over-year.
  • Core operating income rose 14.6% to $2.84 billion, or $7.26 per share, beating analyst estimates of approximately $6.67–$6.78.
  • Consolidated net premiums written reached $14.7 billion, up 3.6% from the prior year.
  • P&C combined ratio improved to 83.8%, reflecting strong underwriting results.
  • Book value per share increased 12.3% year-over-year to $195.45.
  • Earnings exceeded consensus expectations, supporting positive investor focus on core operating performance.

Why Chubb’s Quarterly Results Matter

Chubb Limited, a leading global insurance provider, reports quarterly results that highlight trends in premium growth, underwriting profitability, and investment income. The second-quarter performance provides insight into the company's ability to navigate pricing environments, catastrophe losses, and investment returns amid evolving economic conditions. Investors monitor these figures closely because they influence forward guidance, capital allocation decisions, and valuation multiples for the property and casualty insurance sector.

The Q2 Numbers in Detail

Chubb reported second-quarter 2026 net income of $2.85 billion, or $7.30 per diluted share, compared with $2.96 billion, or $7.59 per share, in the year-ago quarter. Core operating income, a key metric for the company, increased 14.6% to $2.84 billion, or $7.26 per share, surpassing consensus estimates. Consolidated net premiums written rose 3.6% to $14.7 billion, with property and casualty premiums up 3.0% and life insurance premiums up 7.5%. The property and casualty combined ratio improved to 83.8%. Revenue came in slightly below some analyst targets, yet the earnings beat and favorable combined ratio drove the positive takeaway. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

The earnings release followed the typical after-hours schedule on July 21, with the conference call set for the morning of July 22. The EPS beat and improved combined ratio generated positive sentiment heading into the call, as investors focused on the strength in core operating results despite a modest year-over-year decline in reported net income. Historical patterns show Chubb shares often move on the combination of earnings beats and combined ratio performance.

Looking Ahead: Key Factors to Monitor

Investors will focus on management commentary regarding premium growth trends across property and casualty lines and the outlook for rate increases. The combined ratio of 83.8% indicates continued underwriting discipline, and further improvement or stability in this metric will be watched closely.

Net investment income remains an important driver given the size of Chubb’s investment portfolio. Any updates on expected returns or portfolio positioning will help shape expectations for the remainder of the year.

Catastrophe losses and reserve development will also influence results. Analysts typically monitor management guidance on full-year core operating income and any commentary on capital deployment, including share repurchases or acquisitions.

Broader industry conditions, including competitive pricing in commercial lines and regulatory developments, could affect future quarters. The next earnings release is expected in October 2026.

Enhancing My Research with Tickeron Tools

One tool I turn to regularly for deeper market analysis is Tickeron’s AI Screener. It is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. I find it particularly useful when evaluating how a name like Chubb fits into broader sector trends after an earnings release.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for CB turns positive, indicating new upward trend

CB saw its Momentum Indicator move above the 0 level on August 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned positive. In of the 104 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CB advanced for three days, in of 339 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 230 cases where CB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CB moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where CB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CB turned negative on July 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CB broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 51, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.812) is normal, around the industry mean (2.187). P/E Ratio (12.545) is within average values for comparable stocks, (17.710). Projected Growth (PEG Ratio) (2.793) is also within normal values, averaging (8.312). Dividend Yield (0.011) settles around the average of (0.023) among similar stocks. P/S Ratio (2.250) is also within normal values, averaging (1.616).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Industry description

Property and casualty companies insure against accidents of non-physical harm, such as lawsuits, damage to personal assets, car crashes and more. Progressive Corporation, Travelers Companies, Inc. and Allstate Corporation are some of the biggest providers of such products.

Market Cap

The average market capitalization across the Property/Casualty Insurance Industry is 14.27B. The market cap for tickers in the group ranges from 93.9K to 136.58B. CB holds the highest valuation in this group at 136.58B. The lowest valued company is UNAM at 93.9K.

High and low price notable news

The average weekly price growth across all stocks in the Property/Casualty Insurance Industry was 3%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 15%. HRTG experienced the highest price growth at 17%, while ROOT experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Property/Casualty Insurance Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 65
Price Growth Rating: 45
SMR Rating: 60
Profit Risk Rating: 50
Seasonality Score: -18 (-100 ... +100)
View a ticker or compare two or three
CB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company for a family of property and casualty insurance companies

Industry PropertyCasualtyInsurance

Profile
Details
Industry
Property Or Casualty Insurance
Address
Baerengasse 32
Phone
+41 434567600
Employees
40000
Web
https://www.chubb.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.